|
HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GOG partners; Roche/Genentech; Tesaro |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Tesaro |
| |
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech; tesaro |
| |
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Instil Bio (Inst); Sierra Oncology (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech; GlaxoSmithKline; OncoMed; Sutro Biopharma |
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline/Tesaro; Sutro Biopharma |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Oncoceutics |
| |
|
No Relationships to Disclose |
| |
|
Employment - Caris Life Sciences |
Leadership - Caris Life Sciences |
Consulting or Advisory Role - Merck Sharp & Dohme |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
| |
|
Research Funding - Clovis Oncology (Inst) |